CIMS Global Revenue and Competitors
Estimated Revenue & Valuation
- CIMS Global's estimated annual revenue is currently $3.8M per year.
- CIMS Global's estimated revenue per employee is $106,667
Employee Data
- CIMS Global has 36 Employees.
- CIMS Global grew their employee count by 6% last year.
CIMS Global's People
Name | Title | Email/Phone |
---|
CIMS Global Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $17.6M | 110 | 8% | N/A | N/A |
#2 | $2.9M | 26 | 63% | N/A | N/A |
#3 | $13.3M | 83 | 28% | N/A | N/A |
#4 | $9.1M | 63 | -16% | N/A | N/A |
#5 | $42.4M | 241 | 0% | N/A | N/A |
#6 | $0.1M | 9 | 29% | N/A | N/A |
#7 | N/A | 86 | 43% | N/A | N/A |
#8 | $51.9M | 446 | 30% | N/A | N/A |
#9 | $15.7M | 95 | -1% | N/A | N/A |
#10 | $10.9M | 78 | 30% | N/A | N/A |
What Is CIMS Global?
With over 16 years of industry experience, CIMS has pioneered the reshaping of clinical trials. We are committed to revolutionizing the industry through our existing eClinical suite, and expertise in Dynamic Trial Design and Dynamic Data Monitoring. With our proprietary closed system, CIMS empowers pharmaceutical and biotech companies to expedite the drug development process, saving them millions of dollars on clinical trials, and bringing life-saving therapies to patients faster. \n\nOur primary focus lies in the development of innovative eClinical and eHealth solutions, as well as leveraging data sciences for the benefit of the drug and healthcare industries. By combining cutting-edge technology with our deep understanding of the clinical trial landscape, we drive significant advancements and improve patient outcomes.
keywords:N/AN/A
Total Funding
36
Number of Employees
$3.8M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 36 | 16% | N/A |
#2 | $7.3M | 37 | 6% | N/A |
#3 | N/A | 37 | 32% | N/A |
#4 | $9.4M | 38 | 3% | N/A |
#5 | $9.9M | 38 | 6% | N/A |